Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6871-6880

  He, Jin ^a   Yin, Yi ^a   Luster, Troy A ^a   Watkins, Linda ^a   Thorpe, Philip E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BAVITUXIMAB; PHOSPHATIDYLSERINE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; GLIOBLASTOMA; IRRADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GLIOBLASTOMA; GLIOMA; HUMANS; MACROPHAGES; MALE; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLSERINES; RATS; RATS, INBRED F344;

EID: 72549108621     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1499     Document Type: Article

References (45)

1. Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro Oncol 1999;1:205-211
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996
3. Jennewein M, Lewis MA, Zhao D, et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008;14: 1377-1385
4. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002;54:1479-1484 (Pubitemid 35380052)
5. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002;62:6132-6140
6. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995; 358:1-3.
7. Luster TA, He J, Huang X, et al. Plasma protein β-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and an-ionic phospholipids on endothelial cells. J Biol Chem2006;281:29863-29871
8. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005;11:1551-1562 (Pubitemid 40315240)
9. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-427 (Pubitemid 38173977)
10. Beck AW, Luster TA, Miller AF, et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006;118:2639-2643
11. Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 2005;65:4408-4416 (Pubitemid 40775680)
12. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 2007;13:5211-5218 (Pubitemid 47502091)
13. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897-5906
14. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300: 1155-1159
15. Leach JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R, Mikkelsen RB. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 2001;61:3894-3901
16. Bitbol M, Fellmann P, Zachowski A, Devaux PF. Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. Biochim Biophys Acta 1987;904:268-282 (Pubitemid 17158402)
17. Williamson P, Schlegel RA. Back and forth: the regulation and function of transbilayer phospho-lipid movement in eukaryotic cells. Molec Mem Biol 1994;11:199-216.
18. Yang W, Barth RF, Wu G, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 2005;11:341-350
19. Tzeng JJ, Barth RF, Orosz CG, James SM. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 1991;51:2373-2378
20. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998;58: 4646-4653 (Pubitemid 28480630)
21. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92. (Pubitemid 29096240)
22. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998;36:91-102.
23. Barth RF, Yang W, Coderre JA. Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation. J Neurooncol 2003;62:61-74. (Pubitemid 36559478)
24. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15:297-310. (Pubitemid 41677429)
25. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628
26. Rubenstein JL, KimJ, Ozawa T, et al. Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-314
27. Hsieh PC, Chandler JP, Bhangoo S, et al. Adjuvant γ knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery 2005;57:684-692, discussion-92.
28. Balasubramanian K, Schroit AJ. Aminophospholipid asymmetry: A matter of life and death. Annu Rev Physiol 2003;65:701-734 (Pubitemid 38249174)
29. Contreras FX, Villar AV, Alonso A, Kolesnick RN, Goni FM. Sphingomyelinase activity causes transbilayer lipid translocation in model and cell membranes. J Biol Chem 2003;278:37169-37174
30. Clavreul A, Delhaye M, Jadaud E, Menei P. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. J Neurooncol 2006;79:9-17. (Pubitemid 44057410)
31. Paul DB, Barth RF, Yang W, Shen GH, KimJ, Triozzi PL. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Ther 2000;7:993-999
32. Hatterer E, Davoust N, Didier-Bazes M, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 2006; 107:806-812 (Pubitemid 43076409)
33. Pellegatta S, Poliani PL, Corno D, et al. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006;28:527-531 (Pubitemid 44141322)
34. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-4979
35. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-4167 (Pubitemid 40791581)
36. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195:125-133 (Pubitemid 34074502)
37. Groh V, Li YQ, Cioca D, et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 2005;102:6461-6466
38. Banerjee D, Matthews P, Matayeva E, Kaufman JL, Steinman RM, Dhodapkar KM. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcγRs on human dendritic cells. J Immunother 2008;31:113-120
39. Fadok VA, McDonald PP, Bratton DL, Henson PM. Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. BiochemSoc Trans 1998;26:653-656
40. Hoffmann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005; 174:1393-1404
41. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine- dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest 2002;109: 41-50.
42. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-666 (Pubitemid 41400049)
43. Demaria S, Kawashima N, Yang AM, et al. Immune- mediated inhibition of metastases after treatment with local radiation and CTLA-4 block-ade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-734
44. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends in Immunology 2002;23:445-449
45. Bondanza A, Zimmermann VS, Rovere-Querini P, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004;200: 1157-1165